Department of Medical Pathology and Laboratory Medicine, University of California Davis Health System, Sacramento, CA 95817, USA.
Int J Biol Markers. 2011 Jan-Mar;26(1):50-7. doi: 10.5301/jbm.2011.6291.
CD44, a transmembrane glycoprotein receptor, plays a major role in tumor progression and metastasis.
To evaluate the expression of CD44 standard (CD44s) and its variant 6 (CD44v6) in normal and neoplastic lung tissue and correlate it with prognostic factors in lung cancer.
The study included 52 non-small cell lung carcinomas (NSCLC) (21 squamous cell carcinomas and 31 adenocarcinomas), 15 small cell lung carcinomas (SCLC) and 8 carcinoid tumors. Expression of CD44s and CD44v6 was evaluated by immunohistochemistry and correlated with lung cancer prognostic factors.
All squamous cell carcinomas expressed both CD44s and CD44v6. Adenocarcinomas expressed CD44s in 39% of cases and CD44v6 in 45%. Carcinoid tumors expressed only CD44s in 88% of cases. All SCLCs were negative for both CD44s and CD44v6. A restricted panel consisting of CD44s and CD44v6 will discriminate NSCLC from SCLC with a sensitivity of 67% and a specificity of 100%. In adenocarcinoma CD44s expression was significantly correlated with lymph node metastases (p=0.007) while CD44v6 expression was more significantly associated with tumor size (p=0.0032).
CD44s and CD44v6 are expressed in certain types of lung cancer. In adenocarcinoma CD44s and CD44v6 expression is significantly correlated with lymph node metastases and tumor size.
CD44 是一种跨膜糖蛋白受体，在肿瘤的进展和转移中起主要作用。
评估 CD44 标准型（CD44s）和变体 6（CD44v6）在正常和肿瘤肺组织中的表达，并将其与肺癌的预后因素相关联。
本研究纳入了 52 例非小细胞肺癌（NSCLC）（21 例鳞状细胞癌和 31 例腺癌）、15 例小细胞肺癌（SCLC）和 8 例类癌肿瘤。通过免疫组织化学评估 CD44s 和 CD44v6 的表达，并与肺癌的预后因素相关联。
所有鳞状细胞癌均表达 CD44s 和 CD44v6。腺癌中 CD44s 的表达率为 39%，CD44v6 的表达率为 45%。类癌肿瘤中 CD44s 的表达率为 88%。所有 SCLC 均为 CD44s 和 CD44v6 双阴性。由 CD44s 和 CD44v6 组成的简化面板可将 NSCLC 与 SCLC 区分开来，其敏感性为 67%，特异性为 100%。在腺癌中，CD44s 的表达与淋巴结转移显著相关（p=0.007），而 CD44v6 的表达与肿瘤大小的相关性更为显著（p=0.0032）。
CD44s 和 CD44v6 在某些类型的肺癌中表达。在腺癌中，CD44s 和 CD44v6 的表达与淋巴结转移和肿瘤大小显著相关。
